Federal Rescheduling And Medical Expansion Will Support A Stronger Long Term Cannabis Operator

Catalysts

About Trulieve Cannabis

Trulieve Cannabis operates cannabis cultivation, production and retail operations serving primarily medical patients across multiple U.S. states.

What are the underlying business or industry changes driving this perspective?

• Federal reclassification of medical marijuana to Schedule III, along with the ability to register with the DEA and deduct ordinary expenses, is expected to reduce the impact of 280E and could free up more cash to support earnings and operating margins over time.
• Growing medical programs in states such as Texas and Georgia, including potential expansion of qualifying conditions and distribution through independent pharmacies, point to a larger addressable patient pool that may support revenue and gross profit.
• Investments in technology such as Project Hyper and a growing mobile app and rewards ecosystem are designed to sharpen customer targeting and retention, which can support same store sales, marketing efficiency and net margins.
• Expansion of branded products like Modern Flower, Roll One and new premium offerings, together with record wholesale revenue of US$22 million, positions the company to capture more value per unit sold, which can support gross margin and adjusted EBITDA.
• A strong cash position of US$353 million against US$290 million in debt and positive free cash flow of US$42 million in the quarter provide room to fund new stores, production upgrades and possible acquisitions, which can influence future revenue and earnings power.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Trulieve Cannabis's revenue will decrease by 8.2% annually over the next 3 years.
• Analysts assume that profit margins will increase from -6.5% today to 37.4% in 3 years time.
• Analysts expect earnings to reach $339.0 million (and earnings per share of $0.43) by about June 2029, up from -$76.0 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $271.4 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 13.8x on those 2029 earnings, up from -21.5x today. This future PE is lower than the current PE for the US Pharmaceuticals industry at 14.7x.
• Analysts expect the number of shares outstanding to grow by 0.63% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Federal rescheduling and removal of 280E are heavily referenced as positives, but the timing and scope of tax guidance, retroactive relief and DEA registration rules are still uncertain. Any less favorable interpretation could limit the expected tax savings and affect earnings, cash generation and net margins.
• Management highlights expansion in Texas and Georgia, potential conversion of hemp consumers into regulated programs and possible pharmacy distribution. These opportunities rely on regulatory approvals, program awareness and patient adoption that may not materialize as expected, which would cap the long term growth of the addressable market and weigh on revenue and gross profit.
• The company is investing in new production capacity, retail upgrades, Project Hyper and potential acquisitions at the same time that management cites ongoing pricing pressure and softer consumer wallet trends. If consumer demand or pricing does not support these investments, the result could be lower returns on capital, pressured gross margin and weaker earnings.
• Wholesale is described as a growing opportunity with record quarterly revenue of US$22 million, but the company notes that it has historically under indexed to peers and is carefully balancing counterparty risk. Any reversals in wholesale demand, client concentration issues or credit losses could reduce diversification benefits and affect revenue stability and operating margins over the long term.
• Management repeatedly references plans to uplist to a major U.S. exchange, evaluate share buybacks and pursue more active M&A. If these capital allocation choices are timed poorly or regulatory or tax issues constrain flexibility, shareholders could face dilution, higher financing costs or subdued per share earnings despite the current cash balance and free cash flow profile.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $19.42 for Trulieve Cannabis based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $21.0, and the most bearish reporting a price target of just $17.25.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $906.7 million, earnings will come to $339.0 million, and it would be trading on a PE ratio of 13.8x, assuming you use a discount rate of 7.1%.
• Given the current share price of $8.52, the analyst price target of $19.42 is 56.1% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.